Closed-Path Microfluidics for Point-of-Care mRNA Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies for manufacturing and formulating polynucleotide therapeutics, particularly mRNA therapeutics, are prone to contamination and degradation, and centralized production is costly and slow, lacking scalability and point-of-care capabilities.
Innovation Solution
The development of microfluidic apparatuses and devices that operate in a closed path, utilizing a seating mount, fluid vials, fluidic lines, and a controller to drive fluidic movement, enabling in vitro transcription and purification of therapeutic polynucleotides, such as mRNA, in a single-use, disposable format.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If centralized production is used for manufacturing polynucleotide therapeutics, then production capacity is increased, but cost and time increase significantly
Solution Approach 1:
The patent divides the centralized production process into distributed microfluidic units that can operate independently at the point-of-care. Each microfluidic device contains segmented reaction chambers for different processing steps (template synthesis, mRNA transcription, purification) that can be performed in parallel or sequentially in a decentralized manner, eliminating the need for large centralized facilities while maintaining production capacity.
Solution Approach 2:
The patent employs disposable microfluidic devices that are pre-loaded with reagents and designed for single-use or limited-use. These single-use devices eliminate the need for expensive, complex centralized production equipment and can be manufactured at low cost, then distributed to point-of-care locations where they perform therapeutic production functions without requiring maintenance or sterilization infrastructure.
2Productivity
If centralized production is used for manufacturing polynucleotide therapeutics, then production capacity is increased, but contamination risk increases
Solution Approach 1:
The patent segments the production process into isolated microfluidic chambers and channels where each step (template synthesis, mRNA transcription, purification) occurs in a separate, enclosed environment. This physical segmentation prevents cross-contamination between different therapeutic production lines and between reagent storage and reaction zones, while maintaining high production capacity through parallel processing in multiple devices.
Solution Approach 2:
The microfluidic devices are designed with closed fluid pathways that create an inert, contamination-free environment for the therapeutic production process. The sealed microfluidic channels and chambers protect the polynucleotide therapeutics from environmental contaminants including nucleases and other degrading agents, while the system can be operated in sterile conditions without requiring complex centralized sterilization infrastructure.
3Productivity
If centralized production is used for manufacturing polynucleotide therapeutics, then production capacity is increased, but scalability to point-of-care is reduced
Solution Approach 1:
The patent segments the production system into portable microfluidic devices that can be distributed to individual point-of-care locations. Each device is a self-contained unit with integrated reagent delivery, reaction chambers, and purification capabilities, allowing therapeutic production to be scaled from centralized to decentralized settings without requiring infrastructure changes at the point-of-care location.
Solution Approach 2:
The patent uses disposable microfluidic devices that can be manufactured at low cost and distributed widely to point-of-care locations. These single-use devices eliminate the need for expensive, maintainable infrastructure at each location, enabling scalable deployment to hundreds or thousands of point-of-care sites while maintaining production capacity through parallel use of multiple devices.
4Productivity
If conventional manufacturing methods are used, then production capacity is maintained, but manufacturing precision and purity decrease
Solution Approach 1:
The patent segments the manufacturing process into discrete, controlled microfluidic steps with dedicated chambers for template synthesis, mRNA transcription, and purification. Each step is precisely controlled with defined reagent volumes and reaction conditions, enabling high manufacturing precision and therapeutic purity while maintaining production capacity through parallel processing in multiple segmented devices.
Solution Approach 2:
The patent replaces conventional mechanical mixing and handling methods with microfluidic laminar flow and controlled diffusion for reagent mixing and transport. This substitution provides precise control over reagent delivery and reaction conditions, improving manufacturing precision and therapeutic purity while maintaining production capacity through automated, high-speed microfluidic processing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The microfluidic systems provide a controlled, contamination-free environment for therapeutic polynucleotide synthesis and purification, enhancing scalability and suitability for point-of-care applications, reducing costs and time.
Implementation Method 1
a controller configured to drive fluidic movement in the microfluidic path device when the microfluidic path device is seated in the seating mount
Implementation Method 2
each fluidic line is configured to be biased against the microfluidic path device seated in the seating mount with a bias force
Data Source
AI summary
Apparatuses and methods are described herein for processing polynucleotides in a scaled path environment. The apparatuses include optical sensors to monitor operations and to track material usage for good manufacturing practice.